{"url_path":"/sec/apls/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-222923-index.html","accession_number":"0001193125-26-222923","cik":"0001492422","ticker":"APLS","issuer_name":"Apellis Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1492422/0001193125-26-222923-index.html","primary_entity_key":"0001492422","primary_entity_name":"Apellis Pharmaceuticals, Inc."},"word_count":257,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNo.\n\n  \n\nDescription\n\n2.1\n  \n[Agreement and Plan of Merger, dated as of March 31, 2026, by and among Apellis Pharmaceuticals, Inc., Biogen Inc. and Aspen Purchaser Sub, Inc. (incorporated herein by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by Apellis with the SEC on March 31, 2026).†](http://www.sec.gov/Archives/edgar/data/1492422/000119312526134916/d132653dex21.htm)\n\n3.1\n  \n[Amended and Restated Certificate of Incorporation of Apellis Pharmaceuticals, Inc.](d23709dex31.htm)\n\n3.2\n  \n[Amended and Restated Bylaws of Apellis Pharmaceuticals, Inc.](d23709dex32.htm)\n\n4.1\n  \n[First Supplemental Indenture, dated as of May 14, 2026, by and among Apellis Pharmaceuticals, Inc., Biogen Inc. and U.S. Bank Trust Company, National Association, as trustee](d23709dex41.htm)\n\n10.1\n  \n[Contingent Value Rights Agreement, dated as of May 14, 2026, by and among Biogen Inc., Apellis Pharmaceuticals, Inc. and Equiniti Trust Company, LLC](d23709dex101.htm)\n\n99.1\n  \n[Notice of Supplemental Indenture, Fundamental Change and Make-Whole Fundamental Change to Trustee, Paying Agent, Conversion Agent and Holders of the 3.500% Convertible Senior Notes due 2026, dated May 14, 2026](d23709dex991.htm)\n\n104\n  \nCover Page Interactive Data File (formatted as Inline XBRL).\n\n \n\n†\n\nCertain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby agrees to supplementally furnish to the SEC upon request any omitted schedule, exhibit or similar attachment to Exhibit 2.1.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nApellis Pharmaceuticals Inc.\n\nDate: May 14, 2026\n \n\n \n\n \nBy:\n \n\n/s/ Wendell Taylor\n\n \n\n \n\n \n\n \n\n \nName: Wendell Taylor\n\n \n\n \n\n \n\n \n\n \nTitle:  Authorized Signatory"}